{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:39:09Z","timestamp":1781285949065,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007744","name":"University of Maryland Extension","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jdiacomp.2025.109234","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:45:45Z","timestamp":1764175545000},"page":"109234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials"],"prefix":"10.1016","volume":"40","author":[{"given":"Amparo","family":"Ortiz-Seller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Tom\u00e1s","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Morcillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109234_bb0005","series-title":"IDF Diabetes Atlas","author":"Magliano","year":"2025"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0010","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167758","article-title":"Update in the molecular mechanism and biomarkers of diabetic retinopathy","volume":"1871","author":"Zhu","year":"2025","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4239\/wjd.v13.i2.85","article-title":"Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment","volume":"13","author":"Florentin","year":"2022","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27103055","article-title":"Role of dipeptidyl peptidase-4 inhibitors in antidiabetic treatment","volume":"27","author":"Yin","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0035","article-title":"Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12886-024-03535-1","article-title":"Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13061797","article-title":"Novel antidiabetic drugs and the risk of diabetic retinopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Malyszczak","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0050","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/dom.15500","article-title":"Glycemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents","volume":"26","author":"Kunutsor","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.15367","article-title":"Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"26","author":"Igweokpala","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0060","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.13232","article-title":"Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"20","author":"Tang","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2020.100596","article-title":"The effect of dipeptidyl peptidase-4 inhibitors on macrovascular and microvascular complications of diabetes mellitus: a systematic review","volume":"93","author":"Taylor","year":"2020","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2025.01.010","article-title":"An update on ocular effects of antidiabetic medications","author":"Sadeghi","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0075","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00417-023-06236-5","article-title":"Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review","volume":"262","author":"Ntentakis","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0080","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0085","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0095","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12916-021-02166-3","article-title":"ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis","volume":"19","author":"Chiocchia","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0105","first-page":"585","article-title":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: a network meta-analysis","volume":"69","author":"Ortiz-Seller","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.02.016","article-title":"A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis","volume":"157","author":"Nevill","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0115","article-title":"The impact of excluding trials from network meta-analyses - an empirical study","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111839","article-title":"Network meta-regression including baseline risk analysis and interactive visualizations as implemented by the MetaInsight web application","volume":"184","author":"Morris","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0125","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/sim.5539","article-title":"Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis","volume":"32","author":"Achana","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/psp4.12091","article-title":"Model-based network meta-analysis: a framework for evidence synthesis of clinical trial data","volume":"5","author":"Mawdsley","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0135","article-title":"MBNMAdose: dose-response model-based network meta-analysis","author":"Pedder","year":"2022","journal-title":"The Comprehensive R Archive Network"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40272-024-00647-5","article-title":"Comparison of different doses of oral and ocular propranolol for retinopathy of prematurity: a network meta-analysis","volume":"26","author":"Ortiz-Seller","year":"2024","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0145","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s00125-017-4388-y","article-title":"Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes","volume":"60","author":"Hernandez","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1303238","article-title":"Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis","volume":"14","author":"Tan","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0160","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/dom.16114","article-title":"Comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes mellitus: a network meta-analysis","volume":"27","author":"Wang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00592-018-1222-z","article-title":"The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials","volume":"56","author":"Ling","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109234_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/dom.12319","article-title":"Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycemic burden and enhance safety in elderly people with diabetes","volume":"17","author":"Avogaro","year":"2015","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:42:38Z","timestamp":1773862958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1056872725002879"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109234","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"109234"}}